GLP-1 Receptor Agonist Drugs Market to Reach 13.0 billion by 2032

Oral GLP-1 Drugs Are Creating a New Commercial Front in Obesity Treatment

Once-daily pills are beginning to shift GLP-1 competition beyond injectable efficacy toward convenience, patient acquisition, distribution and long-term treatment access

The commercial structure of the GLP-1 receptor agonist market is beginning to change as oral therapies move from a secondary formulation option to a major competitive category. While injectable semaglutide established GLP-1 therapy as one of the most commercially important areas in diabetes and obesity care, the next competitive question is increasingly whether similar pharmacological pathways can reach a wider patient population through pills.

That shift became more significant in April 2026 when the U.S. FDA approved Eli Lilly's Foundayo (orforglipron) for long-term weight reduction in adults with obesity or overweight and at least one weight-related condition. The approval introduced a once-daily small-molecule GLP-1 receptor agonist that does not require injection.

Obesity treatment still reaches only a small portion of the population potentially eligible for pharmaceutical intervention. The underlying GLP-1 market analysis shows a large gap between hundreds of millions of people living with diabetes or obesity and the considerably smaller population receiving persistent pharmacological treatment. Oral therapy could reduce one practical barrier within that gap by giving physicians and patients an alternative to chronic injectable administration.

Lilly began U.S. commercial availability of Foundayo shortly after approval through LillyDirect, telehealth providers and retail pharmacies. The company stated that the drug can be taken once daily without food or water restrictions. Its launch strategy therefore combines a different dosage form with direct distribution and self-pay access rather than relying solely on conventional pharmaceutical channels.

An oral drug may appeal to patients reluctant to begin injections, patients moving from injectable therapy, or primary-care settings where a tablet may fit more naturally into established chronic-disease prescribing patterns. It may also broaden digital prescribing models, where telehealth consultation, electronic prescribing and home delivery can shorten the distance between patient interest and treatment initiation.

Early evidence suggests that the oral transition is becoming commercially visible. A September 2026 real-world study involving patients who switched from injectable weight-loss treatments to an oral Wegovy formulation reported continued weight reduction following the transition. Reuters also reported that oral products had grown to roughly one-third of U.S. obesity prescriptions at the time of the study, demonstrating how quickly formulation preferences can alter an established injectable market.

Competition is consequently moving toward a broader set of product attributes.

Clinical efficacy remains critical, but manufacturers are increasingly competing on dosing simplicity, food restrictions, manufacturing scalability, patient affordability, pharmacy access and the ability to maintain patients on therapy over long periods.

Foundayo also illustrates how oral GLP-1 drugs can extend beyond obesity. Lilly's 2026 ACHIEVE program evaluated orforglipron across type 2 diabetes populations. In June, the company reported Phase III results showing improvements in glycemic control and body weight across several studies, including a comparison with oral semaglutide.

More recent cardiovascular data add another dimension. In September 2026, Lilly reported detailed ACHIEVE-4 results in adults with type 2 diabetes and overweight or obesity at increased cardiovascular risk. Foundayo met the study's primary cardiovascular safety objective compared with insulin glargine while also improving measures including A1C and body weight. These findings concern the diabetes development program and should not be interpreted as a currently approved cardiovascular-risk-reduction indication.

Oral competition is also influencing pharmaceutical dealmaking.

In September 2026, Novo Nordisk agreed to pay up to USD 2.6 billion for rights outside Greater China to Hengrui's experimental HRS-1596, a potential oral GLP-1 therapy. The transaction included USD 300 million upfront and as much as USD 2.3 billion in development and commercial milestones.

That investment illustrates a larger strategic change: companies are no longer treating oral GLP-1 development as merely an alternative formulation program. Oral molecules are becoming assets capable of protecting or expanding obesity and diabetes franchises as the number of competing incretin therapies increases.

For the GLP-1 receptor agonist drugs market, the commercial consequence could be substantial. Injectable therapies created the first large wave of GLP-1 adoption. Oral drugs could create a second access layer by reaching patients who value simpler administration, expanding prescribing channels and giving manufacturers another route for differentiation.

As oral GLP-1 therapies expand, the companies that combine meaningful clinical outcomes with simple dosing, broad reimbursement and scalable patient-access channels may capture patients who previously remained outside long-term incretin treatment.